Search research articles
Contact Us
Filters
Showing results (51-60 of 74) with videos related to
Page
of 8
Sort By:
Journal of Clinical Pharmacology
|
July 22, 2014
Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone
Celine M Laffont, Roberto Gomeni, Bo Zheng, et al.
Journal of Clinical Pharmacology
|
January 7, 2026
Population Pharmacokinetic Model-Based Dose Selection of Extended-Release Injectable Olanzapine (TV-44749) for Subcutaneous Use in Phase 3 Clinical Trial in Adults with Schizophrenia
Itay Perlstein, Irina Cherniakov, Anna Elgart, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
May 30, 2024
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease
Azmi Nasser, Roberto Gomeni, Gianpiera Ceresoli-Borroni, et al.
Journal of Clinical Pharmacology
|
July 16, 2021
Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
Azmi Nasser, Roberto Gomeni, Zhao Wang, et al.
Journal of Psychopharmacology (Oxford, England)
|
July 7, 2011
Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist
Paolo Bettica, Gianluca Nucci, Caroline Pyke, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
April 5, 2024
Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease
Azmi Nasser, Roberto Gomeni, Gianpiera Ceresoli-Borroni, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
January 20, 2019
A General Framework for Assessing In vitro/In vivo Correlation as a Tool for Maximizing the Benefit-Risk Ratio of a Treatment Using a Convolution-Based Modeling Approach
Roberto Gomeni, Lanyan Lucy Fang, Françoise Bressolle-Gomeni, et al.
The AAPS Journal
|
June 22, 2011
Multinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysis
Roberto Bizzotto, Stefano Zamuner, Enrica Mezzalana, et al.
Brain and Behavior
|
February 27, 2023
Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree<sup>®</sup> ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention-deficit/hyperactivity disorder
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Paediatric Drugs
|
September 15, 2021
Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 74) with videos related to
Sort By:
Page
of 8
Journal of Clinical Pharmacology
|
July 22, 2014
Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone
Celine M Laffont, Roberto Gomeni, Bo Zheng, et al.
Journal of Clinical Pharmacology
|
January 7, 2026
Population Pharmacokinetic Model-Based Dose Selection of Extended-Release Injectable Olanzapine (TV-44749) for Subcutaneous Use in Phase 3 Clinical Trial in Adults with Schizophrenia
Itay Perlstein, Irina Cherniakov, Anna Elgart, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
May 30, 2024
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease
Azmi Nasser, Roberto Gomeni, Gianpiera Ceresoli-Borroni, et al.
Journal of Clinical Pharmacology
|
July 16, 2021
Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
Azmi Nasser, Roberto Gomeni, Zhao Wang, et al.
Journal of Psychopharmacology (Oxford, England)
|
July 7, 2011
Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist
Paolo Bettica, Gianluca Nucci, Caroline Pyke, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
April 5, 2024
Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease
Azmi Nasser, Roberto Gomeni, Gianpiera Ceresoli-Borroni, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
January 20, 2019
A General Framework for Assessing In vitro/In vivo Correlation as a Tool for Maximizing the Benefit-Risk Ratio of a Treatment Using a Convolution-Based Modeling Approach
Roberto Gomeni, Lanyan Lucy Fang, Françoise Bressolle-Gomeni, et al.
The AAPS Journal
|
June 22, 2011
Multinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysis
Roberto Bizzotto, Stefano Zamuner, Enrica Mezzalana, et al.
Brain and Behavior
|
February 27, 2023
Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree<sup>®</sup> ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention-deficit/hyperactivity disorder
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Paediatric Drugs
|
September 15, 2021
Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Page
of 8